EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, 4D Molecular Therapeutics's enterprise value is $-250.18 Mil.
4D Molecular Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $0.04 Mil. Therefore, 4D Molecular Therapeutics's EV-to-Revenue for today is -6,761.59.
The historical rank and industry rank for 4D Molecular Therapeutics's EV-to-Revenue or its related term are showing as below:
FDMT'
s EV-to-Revenue Range Over the Past 10 Years
Min: -9925.49 Med: 28.43 Max: 4518.55
Current: -6761.59
During the past 8 years, the highest EV-to-Revenue of 4D Molecular Therapeutics was 4518.55. The lowest was -9925.49. And the median was 28.43.
FDMT's EV-to-Revenue is ranked better than 99.9% of 987
companies
in the Biotechnology industry
Industry Median: 6.76
vs FDMT: -6761.59
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of 4D Molecular Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, 4D Molecular Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4D Molecular Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where 4D Molecular Therapeutics's EV-to-Revenue falls into.
4D Molecular Therapeutics's current Enterprise Value is $-250.18 Mil.
4D Molecular Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4D Molecular Therapeutics's share price for today is $3.08.
4D Molecular Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4D Molecular Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of 4D Molecular Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FDMT has been successfully added to your 